Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2021 | Tagraxofusp: a breakthrough therapy in BPDCN

Naveen Pemmaraju, MD, University of Texas MD Anderson Cancer Center, Houston, TX, talks on the efficacy of tagraxofusp, a CD123-targeted agent, in the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN). The approval of tagraxofusp in the US and in Europe has led to improved outcomes for these patients with a poor prognosis. In addition, a recent study demonstrated that tagraxofusp is efficacious across all age cohorts and has a similar efficacy and toxicity profile across different BPDCN subsets. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.

Disclosures

Naveen Pemmaraju, MD, is a member of the ASH Communications Committee and the ASCO Leukemia Advisory panel; has participated in consultancy work for Pacylex Pharmaceuticals, ImmuniGen, Bristol Myers Squibb, Blueprint Medicines, Clearview Healthcare Partners, Astellas Pharma US Inc., Triptych Health Partners and CTI Biopharma; has received grants from Affymetrix and SagerStrong Foundation; has received honoraria from Incyte, Novartis, LFB Biotechnologies, Stemline Therapeutics, Celgene, AbbVie, MustangBio, Roche Diagnostics, Blueprint Medicines, DAVA Oncology, Springer Science + Business Media LLC, Aptitude Health, NeoPharm Israel and CareDx, Inc., has received research support from Novartis, Stemline Therapeutics, Samus Therapeutics, AbbVie, Cellectis, Affymetrix, Daiichi Sankyo and Plexxikon; and has received travel reimbursement from Stemline Therapeutics, Celgene, MustangBio, DAVA Oncology and AbbVie.